Insilico Medicine, Takeda partner on AI-driven drug discovery

Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates. The deal could include further milestone payments, potentially bringing the total value to approximately $600m. The partnership aims to identify drug candidates with the potential for clinical differentiation across Takeda’s main therapeutic areas. Credit: Gorodenkoff/Shutterstock.com. Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates. Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined…

Salong Debbarma · 2026-07-02

Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates.

Source: Pharmaceutical Technology